RT Journal Article SR Electronic T1 Safety of endovascular therapy for symptomatic intracranial artery stenosis: a national prospective registry JF Stroke and Vascular Neurology JO Stroke Vasc Neurol FD BMJ Publishing Group Ltd SP 166 OP 171 DO 10.1136/svn-2021-000979 VO 7 IS 2 A1 Yabing Wang A1 Tao Wang A1 Adam Andrew Dmytriw A1 Kun Yang A1 Liqun Jiao A1 Huaizhang Shi A1 Jie Lu A1 Tianxiao Li A1 Yujie Huang A1 Zhenwei Zhao A1 Wei Wu A1 Jieqing Wan A1 Qinjian Sun A1 Bo Hong A1 Yongli Li A1 Liyong Zhang A1 Jianfeng Chu A1 Qiong Cheng A1 Yiling Cai A1 Pengfei Wang A1 Qi Luo A1 Hua Yang A1 Baijing Dong A1 Yang Zhang A1 Jun Zhao A1 Zuoquan Chen A1 Wei Li A1 Xiaoxin Bai A1 Weiwen He A1 Xueli Cai A1 Maimai Ti A1 Osama O Zaidat YR 2022 UL http://svn.bmj.com/content/7/2/166.abstract AB Introduction The safety outcomes of endovascular therapy for intracranial artery stenosis in a real-world stetting are largely unknown. The Clinical Registration Trial of Intracranial Stenting for Patients with Symptomatic Intracranial Artery Stenosis (CRTICAS) was a prospective, multicentre, real-world registry designed to assess these outcomes and the impact of centre experience.Methods 1140 severe, symptomatic intracranial arterial stenosis (ICAS) patients treated with endovascular therapy were included from 26 centres, further divided into three groups according to the annual centre volume of intracranial angioplasty and stent placement procedures over 2 years: (1) high volume for ≥25 cases/year; (2) moderate volume for 10–25 cases/year and (3) low volume for <10 cases/year.Results The rate of 30-day stroke, transient ischaemic attack or death was 9.7% (111), with 5.4%, 21.1% and 9.7% in high-volume, moderate-volume and low-volume centres, respectively (p<0.05). Multivariable logistic regression confirmed high-volume centres had a significantly lower primary endpoint compared with moderate-volume centres (OR=0.187, 95% CI: 0.056 to 0.627; p≤0.0001), while moderate-volume and low-volume centres showed no significant difference (p=0.8456).Conclusion Compared with the preceding randomised controlled trials, this real-world, prospective, multicentre registry shows a lower complication rate of endovascular treatment for symptomatic ICAS. Non-uniform utilisation in endovascular technology, institutional experience and patient selection in different volumes of centres may have an impact on overall safety of this treatment.